rs5051 — AGT G-6A

AGT G-6A — The Promoter Switch That Turns Up Blood Pressure

Angiotensinogen (AGT)¹¹ Angiotensinogen (AGT)
the precursor protein for the entire renin-angiotensin-aldosterone system (RAAS) is produced primarily in the liver and released into the bloodstream, where renin cleaves it to angiotensin I. Angiotensin I is then converted by ACE into angiotensin II — the potent vasoconstrictor that raises blood pressure, promotes sodium retention, and drives cardiovascular remodeling. The rs5051 (G-6A) variant sits in the core promoter of the AGT gene, just 6 base pairs upstream of the transcription start site, where it acts as a molecular volume knob for angiotensinogen production.

The Mechanism

The AGT gene sits on the minus (reverse) strand of chromosome 1. In minus-strand notation, the variant is described as G-6A: a guanine-to-adenine substitution at position −6 relative to the transcription start. On the sequencing plus strand (what genome files report), this corresponds to a C-to-T change at rs5051.

The −6 position lies within the core promoter where transcription factors assemble to initiate RNA synthesis. Luciferase reporter assays²² Luciferase reporter assays
a standard molecular technique measuring how powerfully a DNA sequence drives gene expression demonstrate that the A allele at −6 (plus-strand T) drives significantly higher AGT transcriptional activity than the G allele — up to 68.6% more mRNA output³³ up to 68.6% more mRNA output. The adenine at this position likely alters the binding affinity of a transcription factor at or near the core promoter, sustaining higher rates of AGT mRNA synthesis. More AGT mRNA → more angiotensinogen protein → more substrate for renin → more angiotensin I → more angiotensin II → chronically elevated blood pressure.

The Evidence

Powell et al. 2024⁴⁴ Powell et al. 2024
Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension. Chronic Dis Transl Med, 2024 analyzed 311,004 UK Biobank participants and found that rs5051 C>T associates with a 0.35 mmHg increase in systolic blood pressure per T allele (p<0.001). The effect was fourfold larger in Black participants (1.17 mmHg per allele, p=0.032) than in White participants (0.25 mmHg), consistent with the T allele's much higher frequency in African-ancestry populations. The study also confirmed in cell models that rs5051 T increases AGT transcription by up to 68.6% through altered transcription factor binding.

Gu et al. 2011⁵⁵ Gu et al. 2011
A-6G and A-20C Polymorphisms in the Angiotensinogen Promoter and Hypertension Risk in Chinese: A Meta-Analysis. PLoS One, 2011 pooled 15 studies comprising 3,442 hypertensive patients and 3,058 controls. Paradoxically, in Han Chinese populations where the T allele is very common (~83%), the dominant model showed the T (A at −6) allele was associated with lower hypertension risk (OR=0.71, 95%CI 0.57–0.87, p=0.001). Sex-specific analysis found protection was significant in women (OR=0.73) but not men. This apparently counterintuitive result likely reflects population-level confounding from linkage disequilibrium with other AGT haplotype variants, a pattern that differs between East Asian and European populations.

Chen et al. 2012⁶⁶ Chen et al. 2012
Promoter G-6A polymorphism associated with non-familial sick sinus syndrome. PLoS One, 2012 confirmed that the A allele at −6 produces higher AGT promoter transcriptional activity in luciferase assays and found that the G allele (lower AGT expression) was associated with sick sinus syndrome susceptibility — the complement of elevated-AGT effects on blood pressure.

Li et al. 2014⁷⁷ Li et al. 2014
AGT polymorphisms and essential hypertension in Northern Han Chinese. Angiology, 2014 found significantly different A-6G genotype distributions between 652 hypertensive patients and 780 controls (p<0.05) in a Chinese cohort, providing additional population-level evidence of the variant's role in essential hypertension susceptibility.

Practical Actions

Because rs5051 is tightly linked (r²=0.94) with rs699 (M235T), the two variants are almost always inherited together. Their combined effect on AGT expression and blood pressure is larger than either alone. Individuals carrying the T allele at rs5051 who also carry the G allele at rs699 have the highest angiotensinogen-driven blood pressure elevation.

For T allele carriers, the primary actionable implication is that a component of your blood pressure tends to be driven by genetically elevated angiotensinogen substrate supply to the RAAS. This means that RAAS-blocking medications — ACE inhibitors and angiotensin receptor blockers (ARBs) — target the precise upstream mechanism and may be particularly effective for blood pressure management in individuals with this genotype.

Dietary sodium restriction also exerts a larger effect on angiotensinogen-mediated blood pressure, since high sodium intake stimulates RAAS activity, compounding the elevated substrate supply.

Interactions

rs5051 and rs699 (AGT M235T) are almost universally co-inherited (r²=0.94) and function as a functional haplotype. rs5051 affects AGT transcription; rs699 changes the angiotensinogen protein sequence (Met235Thr), which independently affects angiotensinogen protein stability and plasma levels. The haplotype carrying rs5051-T + rs699-G produces the highest combined elevation in plasma angiotensinogen.

The RAAS as a whole is governed by several interacting variants: AGTR1 rs5186 (AT1 receptor, 3' UTR), ACE I/D rs4340 (ACE enzyme level), and CYP11B2 rs1799998 (aldosterone synthase). Individuals carrying multiple RAAS-elevating variants across these genes show compounding hypertension risk beyond the individual variant effects.